Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model

BACKGROUND: The prevalence of patients with gastrointestinal stromal tumourgst (GIST) who fail currently available treatments imatinib and sunitinib (third-line treatment-eligible GIST) is unknown, but is expected to be below an ultra-orphan disease threshold of 2/100,000 population used in England...

Descripción completa

Detalles Bibliográficos
Autores principales: Starczewska Amelio, Justyna M, Cid Ruzafa, Javier, Desai, Kamal, Tzivelekis, Spiros, Muston, Dominic, Khalid, Javaria Mona, Ashman, Philip, Maguire, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039646/
https://www.ncbi.nlm.nih.gov/pubmed/24884940
http://dx.doi.org/10.1186/1471-2407-14-364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039646/
https://www.ncbi.nlm.nih.gov/pubmed/24884940
http://dx.doi.org/10.1186/1471-2407-14-364

Ejemplares similares